China Makes Its Mark On R&D Pipeline And Novel Launches
Executive Summary
The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.